1. Home
  2. PTLO vs IMRX Comparison

PTLO vs IMRX Comparison

Compare PTLO & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portillo's Inc.

PTLO

Portillo's Inc.

HOLD

Current Price

$5.79

Market Cap

396.4M

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.34

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTLO
IMRX
Founded
1963
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.4M
340.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
PTLO
IMRX
Price
$5.79
$5.34
Analyst Decision
Hold
Strong Buy
Analyst Count
11
5
Target Price
$8.06
$17.20
AVG Volume (30 Days)
1.3M
766.3K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.75
EPS
0.27
N/A
Revenue
$732,066,000.00
N/A
Revenue This Year
$9.02
N/A
Revenue Next Year
$5.81
N/A
P/E Ratio
$24.17
N/A
Revenue Growth
3.03
N/A
52 Week Low
$4.41
$1.10
52 Week High
$13.55
$10.08

Technical Indicators

Market Signals
Indicator
PTLO
IMRX
Relative Strength Index (RSI) 47.70 47.18
Support Level $5.27 $5.31
Resistance Level $6.09 $5.36
Average True Range (ATR) 0.33 0.37
MACD -0.02 -0.06
Stochastic Oscillator 28.69 16.98

Price Performance

Historical Comparison
PTLO
IMRX

About PTLO Portillo's Inc.

Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: